A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO [hepatitis B vaccine recombinant].

Next Previous
Trial Profile

A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO [hepatitis B vaccine recombinant].

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Merck & Co

    • Most Recent Events

    • 20 Oct 2009 Actual patient number (1478) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual initiation date changed from 1 Oct 2006 to 1 Sep 2006 as reported by ClinicalTrials.gov.
    • 30 Sep 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top